American Century Companies Inc. Grows Stock Position in Organogenesis $ORGO

American Century Companies Inc. lifted its stake in Organogenesis (NASDAQ:ORGO) by 32.7% in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 131,220 shares of the company’s stock after purchasing an additional 32,328 shares during the period. American Century Companies Inc.’s holdings in Organogenesis were worth $567,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Invesco Ltd. grew its position in shares of Organogenesis by 779.7% during the first quarter. Invesco Ltd. now owns 1,069,252 shares of the company’s stock worth $4,619,000 after purchasing an additional 947,705 shares in the last quarter. Vanguard Group Inc. grew its stake in shares of Organogenesis by 23.4% in the 1st quarter. Vanguard Group Inc. now owns 4,431,414 shares of the company’s stock worth $19,144,000 after buying an additional 841,618 shares in the last quarter. Soleus Capital Management L.P. grew its position in Organogenesis by 5.4% in the fourth quarter. Soleus Capital Management L.P. now owns 12,484,876 shares of the company’s stock worth $39,952,000 after acquiring an additional 645,000 shares in the last quarter. SG Americas Securities LLC boosted its holdings in shares of Organogenesis by 1,158.6% in the 1st quarter. SG Americas Securities LLC now owns 525,421 shares of the company’s stock worth $2,270,000 after purchasing an additional 483,675 shares during the period. Finally, Dimensional Fund Advisors LP boosted its stake in Organogenesis by 18.9% during the fourth quarter. Dimensional Fund Advisors LP now owns 2,789,265 shares of the company’s stock worth $8,925,000 after buying an additional 442,772 shares during the period. 49.57% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of analysts have recently issued reports on the stock. Cantor Fitzgerald boosted their target price on shares of Organogenesis from $7.00 to $9.00 and gave the company an “overweight” rating in a research note on Friday, August 8th. BTIG Research restated a “buy” rating on shares of Organogenesis in a report on Tuesday, July 15th. Two equities research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. Based on data from MarketBeat, Organogenesis presently has a consensus rating of “Moderate Buy” and a consensus price target of $7.50.

Organogenesis Price Performance

Shares of NASDAQ ORGO opened at $5.00 on Friday. Organogenesis has a 12 month low of $2.45 and a 12 month high of $6.71. The stock has a market capitalization of $634.30 million, a price-to-earnings ratio of -35.71 and a beta of 1.75. The firm’s 50 day simple moving average is $4.62 and its 200-day simple moving average is $4.22.

Organogenesis (NASDAQ:ORGO) last released its quarterly earnings results on Thursday, August 7th. The company reported ($0.09) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.01) by ($0.08). Organogenesis had a negative net margin of 1.92% and a negative return on equity of 0.37%. The company had revenue of $101.01 million during the quarter, compared to analyst estimates of $104.75 million. Organogenesis has set its FY 2025 guidance at EPS. Analysts anticipate that Organogenesis will post -0.07 earnings per share for the current fiscal year.

Organogenesis Company Profile

Organogenesis Holdings Inc, a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage.